

May 13, 2025



**Vivoryon Therapeutics N.V.**

Amsterdam

**ISIN NL00150002Q7 / VVY**

**Notice of Annual General Meeting of Shareholders**

This is the notice of the

**annual general meeting of shareholders**

of Vivoryon Therapeutics N.V. (the "**Company**") to be held

**on Tuesday, June 24, 2025 at 1:00 p.m. (CEST),**

**NOTE:** The annual general meeting will be held on Tuesday, June 24, 2025 at 1:00 p.m. (CEST) at the Amsterdam offices of NautaDutilh N.V. at Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "**AGM**").

**I.**  
**Agenda**

**1. Opening**

**2. Report of the Board for the financial year 2024 (*discussion item*)**

This agenda item includes an account of the financial year 2024 by the Board of Directors of the Company (the “**Board**”), including the report of the non-executive members of the Board.

**3. Remuneration report (*advisory voting item*)**

This agenda item concerns an advisory vote on the remuneration report for the financial year 2024 which is set out on pages 46 through 51 of the Company’s annual report 2024. The Board proposes to cast a favorable vote.

**4. 2024 annual accounts (*voting item*)**

The Board proposes to adopt the 2024 annual accounts, as set out on pages 56 through 91 of the Company’s annual report 2024.

**5. Reservation and dividend policy (*discussion item*)**

In accordance with the Dutch corporate governance code and in due observance of the Company’s articles of association, the reservation and dividend policy is dealt with and explained as a separate agenda item.

The Company has not made any distributions of profits, interim distributions of profits and/or other distributions since its incorporation. Pursuant to the Company’s dividend policy as adopted by the Board on April 29, 2021, it is not foreseen that any distributions shall be made on shares in the capital of the Company until the Company generates profits for the first time. Within this framework and subject to the applicable rules of law and the Company’s articles of association, the Company may (but will not be obliged to) at times consider returning capital to its shareholders by making distributions of profits, interim distributions of profits and/or distributions at the expense of any reserve of the Company, or by repurchasing shares if deemed appropriate on the basis of its strategy.

**6. Release from liability of the Company’s executive directors (*voting item*)**

The Board proposes to release the Company’s current and former executive directors from liability for the exercise of their duties in the financial year 2024, insofar as the exercise of those duties is reflected in the 2024 annual accounts or otherwise disclosed to the general meeting prior to the adoption of the 2024 annual accounts.

**7. Release from liability of the Company’s non-executive directors (*voting item*)**

The Board proposes to release the Company’s current and former non-executive directors from liability for the exercise of their duties in the financial year 2024, insofar as the exercise of those duties is reflected in the 2024 annual accounts or otherwise disclosed to the general meeting prior to the adoption of the 2024 annual accounts.

**8. Re-appointment of external auditor (*voting item*)**

The Board proposes, upon a recommendation to that effect by the audit committee of the Board, to re-appoint KPMG Accountants N.V., Laan van Langerhuize 1, 1186 DS Amstelveen, the Netherlands, as external auditor to audit the annual accounts, annual report and, to the extent required, sustainability reporting of the Company for the financial year 2025. Because of the importance of continuity of audit activities, it is desirable to extend the current engagement of the Company's external auditor.

**9. Amendment of the Company's articles of association (*voting item*)**

The Board proposes to amend the Company's articles of association by:

- a. clarifying certain procedural rules on voting in general meetings of the Company;
- b. removing the requirement that the number of non-executive directors should always exceed the number of non-executive directors, in view of the proposed expansion of the number of executive directors (see agenda item 12) which the Board considers to be in the best interests of the Company;
- c. amending the rules in case there would be a tie in the voting of the Board in such a way that the Chairman of the Board or his deputy would have a casting vote provided that there are at least 3 Board members in office, which arrangement is designed to safeguard the checks and balances embedded in our governance in view of the expansion of the Board as noted above.

As part of this resolution, each civil law notary, candidate civil law notary and lawyer working with NautaDutilh N.V. is authorised to execute the deed of amendment to the Company's articles of association. The draft deed of amendment to the Company's articles of association drawn up by NautaDutilh N.V. is available at the Company's offices and on its website.

**10. Re-appointment of Dr. Frank Weber as executive director (*voting item*)**

Upon the closing of this AGM, the term of office of the executive director Dr. Weber will expire. In accordance with article 15.4 of the Company's articles of association, the Board, by way of binding nomination, proposes to re-appoint Dr. Weber as executive director until the closing of the annual general meeting of the Company to be held in 2026. Dr. Weber will continue to serve as Chief Executive Officer and Chief Medical Officer.

**Reasons for nomination for re-appointment:**

Dr. Frank Weber has been Vivoryon's Chief Executive Officer since August 2023 and has served as the Company's Chief Medical Officer since 2010. With 30 years of experience in the pharmaceutical and life science industry, he demonstrated strong leadership by spearheading the strategic transformation of the Company in the past twelve months.

Dr. Weber supported InterMune (now Genentech/Roche), in particular, its launch of Esbriet in Europe, as Global Clinical Advisor. Prior to this, he served as Chief Medical Officer at Merck KGaA in Germany and Switzerland, where he contributed to several marketing authorizations and market access agreements in the EU, U.S. and Japan and also spearheaded personalized medicine, biomarker and companion diagnostics. During his career, he has also been involved in several M&A transactions as well as licensing deals. His past roles include management positions in medical affairs and clinical development at American Cyanamid (Lederle), USA and at Synthelabo (now Sanofi), France. Dr. Weber is also a board member at Zambon Biotech SA.

He started his industry career after 10 years in academic clinical research and patient care in the areas of cancer, immunology, infectiology and maxillo-facial surgery. He is a licensed physician and received his MD in Cancer Immunology from the Medical University Cologne, Germany.

Extension of Service Contract and Remuneration:

A summary of the main elements of Dr. Weber's management agreement with the Company is enclosed as an Annex.

**11. Re-appointment of Anne Doering as executive director (*voting item*)**

Upon the closing of this AGM, the term of office of the executive director Ms. Doering will expire. In accordance with article 15.4 of the Company's articles of association, the Board, by way of binding nomination, proposes to re-appoint Ms. Doering as executive director until the closing of the annual general meeting of the Company to be held in 2027. Ms. Doering will continue to serve as Chief Financial Officer.

Reasons for nomination for re-appointment:

Anne Doering has been Vivoryon's Chief Financial Officer since March 2024 and has served as the Company's Chief Strategy & Investor Relations Officer since August 2023. She brings over 25 years of capital markets, investment and corporate biopharmaceutical industry experience which allows her to proactively drive the Company's financial strategy.

Prior to joining Vivoryon, Ms. Doering was Director of Investor Relations at BioNTech and Director of Group Strategy at Merck KGaA, where she contributed to the strategic direction of the company. Her additional corporate experience includes R&D finance and strategy at Merck & Co. On the investment front, Ms. Doering helped build the Franklin European Equity Funds franchise at Franklin Templeton, a leading global asset manager, as portfolio manager and analyst and has spent time in venture capital at Creathor Ventures in Germany. In addition, for several years Ms. Doering was a healthcare equity research analyst covering pharmaceutical companies for a number of investment banks in New York including Bear Stearns, Credit Suisse, Bank of America and Commerzbank, during which time she was instrumental in the team achieving a #1 Institutional Investor ranking. Ms. Doering holds an MBA from The Wharton School and an MA in International Studies from The Lauder Institute, both of the University of Pennsylvania. She is also a Chartered Financial Analyst (CFA) Charterholder.

Extension of Service Contract and Remuneration:

A summary of the main elements of Ms. Doering's management agreement with the Company is enclosed as an Annex.

**12. Appointment of Dr. Julia Neugebauer as executive director (*voting item*)**

Conditional upon the adoption of agenda item 9, and in accordance with article 15.4 of the Company's articles of association, the Board, by way of binding nomination, proposes to appoint Dr. Julia Neugebauer as executive director until the closing of the annual general meeting of the Company to be held in 2027.

With nearly 20 years of experience in the biotech industry, Dr. Neugebauer has successfully combined scientific expertise with business acumen to become a strategic leader in investor relations. In her previous role as Vice President, Global Head of Investor Relations & Sustainability at MorphoSys AG, she led all investor relations activities and was a member of

the Finance Leadership Team. Dr. Neugebauer brings deep expertise in developing and executing global investor relations strategies, with a strong track record of cultivating long-term relationships with institutional investors and both buy- and sell-side analysts. She played a key role in shaping investor messaging around corporate milestones, clinical data, and financial performance, and was responsible for the investor relations aspects of quarterly and annual financial reporting under IFRS and Form 20-F. She also ensured compliance with capital market regulations related to MorphoSys's dual listings on the Frankfurt Stock Exchange and NASDAQ. She started her career in investor relations after more than 10 years in R&D, with a focus on antibody engineering and development. Dr. Neugebauer holds a PhD from the Ludwig-Maximilians-Universität München, Germany, and is a Certified Investor Relations Officer (CIRO) through the Frankfurt School of Finance & Management.

#### Service Contract and Remuneration:

A summary of the main elements of Dr. Neugebauer's management agreement with the Company is enclosed as an Annex.

### **13. Re-appointment of Dr. Erich Maximilian Oswald Platzer as non-executive director (*voting item*)**

Upon the closing of this AGM, the term of office of the non-executive director Dr. Platzer will expire. In accordance with article 15.4 of the Company's articles of association, the Board, by way of binding nomination, proposes to re-appoint Dr. Platzer as non-executive director until the closing of the annual general meeting of the Company to be held in 2027. Dr. Platzer will continue to serve as the Chairman of the Board.

#### Profile of the proposed candidate:

Date of birth:	July 25, 1950
Nationality:	Swiss
Current position:	Non-executive member and Chairman of the Board
Date of initial appointment:	November 28, 2020
Current term in office:	4,5 years
Shares held in the Company:	355,409 from investments

Dr. Platzer has served as a non-executive director on the Board since 2007. He is a business angel and board member of Swiss angel organization StartAngels-Network, focusing on Life Sciences and technology investments. In addition, he serves as an advisor to Swiss venture capital firm MTIP in Basel, which focuses on medtech and e-health investments. Prior to this, he was an investment advisor and industry partner at HBM Partners AG, a venture capital company, which he co-founded in 2001. Dr. Platzer has been chairman or board member of various biotech or medtech companies, public or private, in the U.S., Europe and Israel.

Until 1999, Dr. Platzer worked in various functions in product development and marketing at F. Hoffmann — La Roche, Basel, most recently as Business Director Oncology (worldwide). Prior to that, he worked in academic medicine and research and had a key role in the team at MSKCC that purified natural human G-CSF, which lead to the development of Neupogen® and,

ultimately, Neulasta®. Dr. Platzer holds an MD from the Medical Faculty of the University of Erlangen, Germany, where he also earned his MD PhD (Habilitation).

Reasons for nomination for re-appointment:

Dr. Erich Platzer has been a non-executive member of the Board since the conversion of the Company into a Dutch N.V. in 2020, and has been a supervisory board member of Vivoryon Therapeutics N.V. (previously named: Probiodrug AG and Vivoryon Therapeutics AG) since the 2007 annual general meeting, from 2015 as chairman of the Board. Dr. Platzer is a seasoned industry expert with extensive know-how in life sciences investments. Due to his experience and valuable contributions to the Company, the Board is of the opinion that Vivoryon will continue to benefit from Dr. Platzer's membership as non-executive member of the Board.

**14. Re-appointment of Ms. Eva Charlotte Lohmann as non-executive director (voting item)**

Upon the closing of this AGM, the term of office of the non-executive director Ms. Lohmann will expire. In accordance with article 15.4 of the Company's articles of association, the Board, by way of binding nomination, proposes to re-appoint Ms. Lohmann as non-executive director until the closing of the annual general meeting of the Company to be held in 2028.

Profile of the proposed candidate:

Date of birth:	November 5, 1970
Nationality:	German and Swedish
Current position:	Non-executive member of the Board
Date of initial appointment:	November 28, 2020
Current term in office:	4,5 years
Shares held in the Company:	0

Charlotte Lohmann has served as a non-executive director on the Board since 2015 and as vice chair since 2025. She served as General Counsel at MorphoSys AG in Planegg, Germany from May 2012 until November 2024 and was appointed Chief Legal & HR Officer in 2023. She was also a member of the Executive Committee at MorphoSys from June 2020 until November 2024. Prior to this, she spent eleven years at Wilex AG in Munich, most recently as Senior Vice President Legal Affairs & Human Resources. Prior to her position at Wilex, she practiced law at the law firm KPMG Treuhand & Goerdeler GmbH in Munich. Ms. Lohmann started her career in the tax and law department of the auditing company KPMG Deutsche Treuhand-Gesellschaft AG. Currently, she is working as an independent lawyer in her own law firm. Ms. Lohmann received her degree in law from the Ludwig Maximilians University of Munich and is a licensed attorney.

Reasons for nomination for re-appointment:

Charlotte Lohmann has been a non-executive member of the Board since the conversion of the Company into a Dutch N.V. in 2020, and has been a supervisory board member of Vivoryon Therapeutics AG (previously named: Probiodrug AG and Vivoryon Therapeutics AG) since the 2015 annual general meeting. She qualifies as a corporate legal and financial expert due to many years of professional practice. Ms. Lohmann is also familiar with the sector in which the Company operates. Due to Charlotte Lohmann's experience and valuable contributions to the

Company, the Board is of the opinion that Vivoryon will continue to benefit from Ms. Lohmann's membership as non-executive member of the Board.

**15. Re-appointment of Dr. Claudia Riedl as non-executive director (*voting item*)**

Upon the closing of this AGM, the term of office of the non-executive director Dr. Riedl will expire. In accordance with article 15.4 of the Company's articles of association, the Board, by way of binding nomination, proposes to re-appoint Dr. Riedl as non-executive director until the closing of the annual general meeting of the Company to be held in 2027.

Profile of the proposed candidate:

Date of birth:	September 4, 1970
Nationality:	German
Current position:	Non-executive member of the Board
Date of initial appointment:	June 22, 2022
Current term in office:	3 years
Shares held in the Company:	1,000 from investments

Dr. Claudia Riedl has served as a non-executive director on the Board since 2022 and as chair of the audit committee since 2023. As Senior Advisor at MC Services AG, she supports various clients in the biotechnology industry in all aspects of investor relations and corporate communications. During her more than 15-year tenure as Head of Corporate Communications and Investor Relations at the German biotech MorphoSys AG until 2016, she supported the company's transformation and growth from a technology-focused antibody discovery and development enterprise into a fully integrated biopharmaceutical company. Subsequently, in a senior advisor capacity, she was instrumental in the company's successful secondary listing on Nasdaq in 2018. Following an apprenticeship at Deutsche Bank AG, Dr. Riedl studied biology and earned a PhD at Technical University, Munich, Germany.

Reasons for nomination for re-appointment:

Dr. Riedl has been a non-executive member of the Board since the 2022 annual general meeting. She qualifies as a financial expert due to many years of professional practice. Dr. Riedl is also familiar with the sector in which the Company operates. Due to her experience and valuable contributions to the Company, the Board is of the opinion that Vivoryon will continue to benefit from Dr. Riedl's membership as non-executive member of the Board.

**16. Re-appointment of Dr. Samir Shah as non-executive director (*voting item*)**

Upon the closing of this AGM, the term of office of the non-executive director Dr. Shah will expire. In accordance with article 15.4 of the Company's articles of association, the Board, by way of binding nomination, proposes to re-appoint Dr. Shah as non-executive director until the closing of the annual general meeting of the Company to be held in 2028.

Profile of the proposed candidate:

Date of birth:	November 15, 1961
----------------	-------------------

Nationality:	Swiss and British
Current position:	Non-executive member of the Board
Date of initial appointment:	June 22, 2022
Current term in office:	3 years
Shares held in the Company:	0

Dr. Shah has served as a non-executive director on the Board since 2022. His current role is in Public Affairs and Special Projects for Asia Pacific region for Novartis and as a member of Novartis' Innovation Management Board. Dr. Shah led Investor Relations for Novartis for over a decade, a company he has been with since 2004. He has been a member of several executive groups and committees within the organization, including Finance Leadership Team and Trust & Reputation Committee. Prior to Novartis, Dr. Shah spent more than 12 years at Merck Serono, where he led several global franchises, including neurology. He graduated as a physician from University of Sheffield, England and joined the pharmaceutical industry after completing his postgraduate medical training (MRCP). He also holds an MBA from the University of Warwick, England.

Reasons for nomination for re-appointment:

Dr. Shah has been a non-executive member of the Board since the 2022 annual general meeting. He brings senior executive, business development, commercial, financial and investor relations expertise to Vivoryon. Due to his experience and valuable contributions to the Company, the Board is of the opinion that Vivoryon will continue to benefit from Dr. Shah's membership as non-executive member of the Board.

**17. Remuneration non-executive directors of the Board (voting item)**

The remuneration of the non-executive directors was most recently approved by the general meeting held on June 22, 2022. In addition hereto, the Board proposes, upon recommendation by the compensation committee of the Board, to grant a one-time share based remuneration to all incumbent non-executive members of the Board,) as set out below, all in accordance with the company's long term incentive plan 2021 as approved by the general meeting on June 28, 2021 (the "**LTIP 2021**"). Capitalized terms used below have the meaning ascribed thereto in the LTIP 2021.

Number of share options per non-executive director:	25,000 Options
Vesting period:	Three years in accordance with the LTIP 2021.
Exercise Price:	The Fair Market Value on the Date of Grant
Date of Grant:	June 24, 2025

**18. Delegation of the authority of the Board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the Company for 10% of the Company's issued share capital (*voting item*)**

The Board has been designated as the corporate body authorised to (i) to resolve to issue ordinary shares in the Company's capital and/or to grant rights to subscribe for ordinary shares in the Company's capital up to the Company's authorised capital included in the articles of association from time to time and (ii) to resolve upon the limitation or exclusion of pre-emption rights in relation to any issuance of ordinary shares in the Company's capital or granting of rights to subscribe for such ordinary shares which the Board is authorised to perform, for a period ending on November 27, 2025.

The Board is now seeking authorization for a period of 18 months from November 28, 2025 to issue ordinary shares and grant rights to subscribe for ordinary shares, for any purpose, up to a maximum of 10% of the Company's issued share capital, provided that the above-mentioned percentage shall be calculated by reference to the Company's issued share capital determined as at the close of business on November 28, 2025.

**19. Delegation of the authority of the Board to limit or exclude pre-emptive rights in connection with an issuance of shares or a grant of rights to subscribe for ordinary shares in the capital of the Company for 10% of the Company's issued share capital (*voting item*)**

The Board is seeking authorization for a period of 18 months from November 28, 2025 to limit or exclude pre-emptive rights in connection with an issuance of shares or a grant of rights to subscribe for ordinary shares in the capital of the Company resolved upon by the Board under the authorization described in agenda item 18 above.

**20. Delegation of the authority of the Board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the Company for 50% of the Company's issued share capital in connection with one or more potential capital raises, or for other strategic purposes (*voting item*)**

The Board is seeking further authorization for a period of 2 years from November 28, 2025 to issue ordinary shares and grant rights to subscribe for ordinary shares up to a maximum of 50% of the Company's issued share capital in connection with one or more potential capital raises, including in public offerings or private placements (such as a private investment in public equity (PIPE) or an accelerated bookbuild offering (ABB)), or in connection with other financing arrangements or other (strategic) transactions involving the issuance of ordinary shares or rights to subscribe for ordinary shares, with the exact size, timing and method to be determined by the Board or a committee of the Board, provided that the above-mentioned percentage shall be calculated by reference to the Company's issued share capital determined as at the close of business on November 28, 2025.

**21. Delegation of the authority of the Board to limit or exclude pre-emptive rights in connection with an issuance of shares or a grant of rights to subscribe for ordinary shares in the capital of the Company for 50% of the Company's issued share capital (*voting item*)**

The Board is seeking authorization for a period of 2 years from November 28, 2025 to limit or exclude pre-emptive rights in connection with an issuance of shares or a grant of rights to subscribe for ordinary shares in the capital of the Company resolved upon by the Board under the authorization described in agenda item 20 above.

**22. Authorization to acquire own shares (*voting item*)**

The Board proposes to renew the authorization of the Board to acquire shares in the capital of the Company for valuable consideration, for a period of 18 months from the date of the AGM. The number of shares that may be so acquired will not exceed 10% of the Company's issued share capital (determined at the end of the date of the AGM). Shares may be acquired at the stock exchange or otherwise, at a price for each share higher than nil and up to 110% of the average opening price at Euronext Amsterdam N.V. over the five consecutive trading days preceding the date of the purchase of such share.

The purpose of this proposal is to give the Board the authorization to reduce the Company's share capital in order to return capital to the Company's shareholders and/or to cover obligations under share-based compensation plans, or for other purposes.

**23. Closing**

## II. Other details of the notice

### 1. Information and documents

The agenda and explanatory notes (including the Annexes) are available for viewing and downloading on the Company's website at <https://www.vivoryon.com/2025-annual-general-meeting/>. Moreover, they are available free of charge at the office of the Company (address: Weinbergweg 22, 06120 Halle (Saale), Germany) during the usual business hours of the Company from Monday through Friday from 9:00 a.m. until 3:00 p.m. (CEST).

### 2. Procedure for participation

#### Record date

Those persons who on **Tuesday, May 27, 2025** after close of trading on Euronext Amsterdam (the "**Record Date**") (i) are shareholders of the Company or otherwise have voting rights and/or meeting rights with respect to shares in the Company's capital and (ii) are recorded as such in the Company's shareholders' register and/or any register maintained by an intermediary (*intermediair*) for purposes of the administration of shares included in a collective deposit (*verzameldepot*) pursuant to the Dutch Giro Securities Transfer Act (*Wet giraal effectenverkeer*), will be regarded as having the right to vote and/or attend, as applicable, the general meeting ("**Eligible Participants**").

#### Application

Eligible Participants (or their authorised representatives) who wish to attend the general meeting must apply as from the Record Date and no later than on **Tuesday, June 17, 2025, 6:00 p.m. (CEST)** (the "**Cut-off Time**") via their own intermediary to:

Vivoryon Therapeutics N.V.  
c/o Computershare Operations Center  
80249 München, Germany

E-mail: [anmeldestelle@computershare.de](mailto:anmeldestelle@computershare.de)

In all circumstances, the intermediaries will need to issue a statement to Vivoryon Therapeutics N.V., c/o Computershare Operations Center as mentioned above, no later than **Tuesday, June 17, 2025, 6:00 p.m. (CEST)**, stating the number of shares held (or in respect of which rights can be exercised) on the Record Date by the Eligible Participant concerned which have been applied for registration. In addition, the intermediaries are requested to include the full address details as well as the valid e-mail address of the relevant Eligible Participant in order to be able to verify the shareholding (or other rights to shares) on the Record Date in an efficient manner.

The Company or Computershare on its behalf will provide each Eligible Participant that has been duly registered in accordance with the procedure above by e-mail a confirmation of registration (such email the "**Confirmation of Registration**") by electronic means.

#### Attendance in person

If an Eligible Participant (or an authorised representative) wishes to attend the meeting in person and provided he/she has submitted his/her application to attend the general meeting in time in the manner set out above, he/she is kindly requested (in addition to following the procedure for participation as outlined above) to send an email to the Company, at [investor@vivoryon.com](mailto:investor@vivoryon.com), ultimately by the Cut-off Time. The Company will then send the relevant Eligible Participant by e-mail a confirmation of attendance (the “**Confirmation of Attendance**”). **Eligible Participants who have not submitted a request and who have not received a Confirmation of Attendance will not be admitted to the meeting.**

Only Eligible Participants (and their authorised representatives) holding (i) their Confirmation of Registration, (ii) their Confirmation of Attendance, (iii) in case of an authorized representative, their completed and signed proxy form (see also below), and (iv) a valid identification document, will be admitted to the meeting. Registration for admission in person to the meeting will take place from 12:30 p.m. (CEST) until the commencement of the meeting at 1:00 p.m. (CEST). After this time registration is no longer possible.

#### Attendance by proxy

Eligible Participants who have been duly registered may grant a proxy to have themselves represented at the meeting. Such a proxy may be granted either to any third party or to Mr. P.C.S. van der Bijl, civil law notary in Amsterdam, the Netherlands, and/or any other civil law notary or candidate civil law notary working with NautaDutilh N.V.

A form for granting such a proxy is available on the Company’s website at <https://www.vivoryon.com/2025-annual-general-meeting/>. The completed proxy form should be received ultimately by the Cut-off Time at the following address or e-mail address:

Vivoryon Therapeutics N.V.  
c/o Computershare Operations Center  
80249 München, Germany

E-mail: [anmeldestelle@computershare.de](mailto:anmeldestelle@computershare.de)

### **3. Number of issued shares and voting rights**

At the time of convening the general meeting, the Company’s issued share capital amounts to € 260,668.09 and is divided in 26,066,809 shares, of which at the opening of trading on Euronext Amsterdam 8 shares are held by the Company as treasury shares. Each share confers one vote. Accordingly, at the date of convening the general meeting, the total number of voting rights in the Company is 26,066,809. No votes may be cast in the AGM on shares that have been repurchased by the Company.

Halle (Saale), May 13, 2025

Vivoryon Therapeutics N.V.

The Board

#### **Contact information:**

Vivoryon Therapeutics N.V.  
Weinbergweg 22,  
06120 Halle (Saale), Germany  
Telephone: +49 (0)345 555 99 00

e-mail: [investor@vivoryon.com](mailto:investor@vivoryon.com)  
website: [www.vivoryon.com](http://www.vivoryon.com)

**III.**  
**Annexes**